821 related articles for article (PubMed ID: 16234500)
1. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
Schneider LS; Dagerman KS; Insel P
JAMA; 2005 Oct; 294(15):1934-43. PubMed ID: 16234500
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.
Schneider LS; Dagerman K; Insel PS
Am J Geriatr Psychiatry; 2006 Mar; 14(3):191-210. PubMed ID: 16505124
[TBL] [Abstract][Full Text] [Related]
3. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Ballard C; Waite J
Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis.
Yunusa I; Alsumali A; Garba AE; Regestein QR; Eguale T
JAMA Netw Open; 2019 Mar; 2(3):e190828. PubMed ID: 30901041
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.
Maher AR; Maglione M; Bagley S; Suttorp M; Hu JH; Ewing B; Wang Z; Timmer M; Sultzer D; Shekelle PG
JAMA; 2011 Sep; 306(12):1359-69. PubMed ID: 21954480
[TBL] [Abstract][Full Text] [Related]
7. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials.
Ma H; Huang Y; Cong Z; Wang Y; Jiang W; Gao S; Zhu G
J Alzheimers Dis; 2014; 42(3):915-37. PubMed ID: 25024323
[TBL] [Abstract][Full Text] [Related]
9. Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.
Yunusa I; Rashid N; Demos GN; Mahadik BS; Abler VC; Rajagopalan K
Adv Ther; 2022 May; 39(5):1993-2008. PubMed ID: 35247186
[TBL] [Abstract][Full Text] [Related]
10. Mortality in elderly dementia patients treated with risperidone.
Haupt M; Cruz-Jentoft A; Jeste D
J Clin Psychopharmacol; 2006 Dec; 26(6):566-70. PubMed ID: 17110812
[TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Daiello LA
Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
[TBL] [Abstract][Full Text] [Related]
12. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
13. Selection of atypical antipsychotics for the management of schizophrenia.
Sprague DA; Loewen PS; Raymond CB
Ann Pharmacother; 2004 Feb; 38(2):313-9. PubMed ID: 14742771
[TBL] [Abstract][Full Text] [Related]
14. The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia.
Isaac M; Koch A
Eur Neuropsychopharmacol; 2010 Mar; 20(3):139-45. PubMed ID: 20053539
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis.
Tan L; Tan L; Wang HF; Wang J; Tan CC; Tan MS; Meng XF; Wang C; Yu JT
Alzheimers Res Ther; 2015; 7(1):20. PubMed ID: 25897331
[TBL] [Abstract][Full Text] [Related]
16. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
17. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.
Nelson JC; Papakostas GI
Am J Psychiatry; 2009 Sep; 166(9):980-91. PubMed ID: 19687129
[TBL] [Abstract][Full Text] [Related]
18. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.
Ballard C; Hanney ML; Theodoulou M; Douglas S; McShane R; Kossakowski K; Gill R; Juszczak E; Yu LM; Jacoby R;
Lancet Neurol; 2009 Feb; 8(2):151-7. PubMed ID: 19138567
[TBL] [Abstract][Full Text] [Related]
19. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials.
Pringsheim T; Lam D; Ching H; Patten S
Drug Saf; 2011 Aug; 34(8):651-68. PubMed ID: 21751826
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
